Short-acting b2-adrenergic receptor agonists are commonly used bronchodilators for
symptom relief in asthmatics. The aim of this study was to test whether genetic variants in …

Abstract PDE4D (Phosphodiesterase 4D) gene encodes a hydrolase of cyclic AMP. PDE4D
genetic variants have been associated with asthma susceptibility. Therefore, this study …

β2-Adrenergic receptor (β2AR) agonists induce airway relaxation via cAMP.
Phosphodiesterase (PDE) s degrade and regulate cAMP, and in airway smooth muscle …

Background With β‐agonists being the most widely used agents in the treatment of asthma,
in vitro studies reported that β2‐adrenergic receptor (ADRB2) polymorphisms are …

Activation of the cyclic AMP (cAMP) signaling pathway leads to the suppression of
inflammation in the airways and relaxation of airway smooth muscle. Intracellular cAMP …

Background In vitro and some in vivo studies suggested that genetic haplotypes may have
an impact on β 2-agonist mediated airway responses in asthmatics. Due to strong linkage …

Background and objective: Whether β2‐adrenoceptor gene (ADRB2) polymorphisms are
associated with airway responsiveness to β2‐agonist medications remains controversial …

Abstract Background and Objectives Genome Wide Association Studies (GWAS) have
identified genetic polymorphisms associated with bronchodilator response (BDR), but it is …

Asthma, a chronic airway disease with known heritability, affects more than 300 million
people around the world. A genome-wide association (GWA) study of asthma with 359 …

Genetic variation may partly explain asthma treatment response heterogeneity. We aimed to
identify common and rare genetic variants associated with asthma that was not well …